Skip to main content

Table 1 Examples of cytotoxic and targeted drugs showing promising activity towards hereditary cancers

From: Cytotoxic and targeted therapy for hereditary cancers

Hereditary cancer type Drug
BRCA1/2-driven cancers (breast, ovarian, prostate, pancreatic, stomach, etc.) Genotoxic agents: platinum compounds, PARP inhibitors, mitomycin C, pegylated doxorubicin, etc.; high dose chemotherapy
Hereditary non-polyposis colorectal cancer Immune checkpoint inhibitors: pembrolizumab
Familial adenomatous polyposis Non-steroidal anti-inflammatory drugs (sulindac) and EGFR inhibitors (erlotinib)
Tumors arising in patients with tuberous sclerosis (giant-cell astrocytomas, angiomyolipomas) mTOR inhibitors: everolimus
Tumors associated with the basal-cell nevus syndrome (basal-cell carcinomas, keratocystic odontogenic tumors) SMO inhibitors (vismodegib), COX2 inhibitors (celecoxib), antifungal drugs with Hedgehog pathway inhibitory activity (itraconazole)
Hereditary medullary thyroid cancer RET inhibitors (vandetanib, cabozantinib)
  1. Note: See the text for comments and references